Cannabis News Box

GW Pharmaceuticals turns over $108M in Q4 sales thanks to CBD-based medicine

GW Pharmaceuticals turns over $108M in Q4 sales thanks to CBD-based medicine

Bethan Rose Jenkins, Cannabis News Writer/Editorial

January 27, 2020

Following the EU approval of a cannabis-derived epilepsy treatment called Epidiolex, British drugs company GW Pharmaceuticals is experiencing a major surge in sales. Headquartered in London, GW Pharma recently revealed its latest sales figures to investors; $108 million during the last quarter of 20...

CEO of GW Pharma talks about Epidiolex getting FDA approval

CEO of GW Pharma talks about Epidiolex getting FDA approval

Bethan Rose Jenkins, Cannabis News Writer/Editorial

July 2, 2018

On Monday, Justin Gover hit a milestone in his career. He is the CEO of GW Pharmaceuticals – a company that created a cannabis-based medicine called Epidiolex. Not only is Epidiolex being used to treat two forms of epilepsy but also, it is non-psychoactive, what with it containing the cannabis com...

Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?

Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?

Bethan Rose Jenkins, Cannabis News Writer/Editorial

May 3, 2018

A cannabis-based medication for epilepsy could be the first to gain approval by the Food and Drug Administration (FDA). Created by British company GW Pharmaceuticals, cannabis-based epilepsy treatment Epidiolex will undergo FDA review this June. Things are looking hopeful, with a panel of 13 advisors...

gw pharma